Table 1.
Population characteristics
| Characteristic | |
|---|---|
| Demographics | |
| Male (n (%)) | 40 (95.2%) |
| Age (years) | 63 ± 13.2 |
| Gout duration (years) | 7.9 ± 9.6 |
| Familial gout (n (%)) | 7 (16.7%) |
| Number of flares per year | 4.1 ± 6.6 |
| Alcohol consumption (g/day) | 15 ± 20.7 |
| Creatinine clearance (ml/min) | 80.0 ± 31.1 |
| Cardiovascular risk factors | |
| Body mass index (kg/m2) | 30.2 ± 5.7 |
| Total cholesterol (mg/dL) | 177 ± 63 |
| HDL cholesterol (mg/dL) | 44 ± 13 |
| LDL cholesterol (mg/dL) | 97 ± 43 |
| Triglycerides (mg/dL) | 207 ± 393 |
| Systolic blood pressure (mmHg) | 132.8 ± 13.7 |
| Diastolic blood pressure (mmHg) | 77 ± 9.9 |
| Smoker (n (%)) | 6 (14.3%) |
| Metabolic syndrome (n (%)) | 28 (66.7%) |
| Cardiovascular comorbidities | |
| Coronary heart disease (n (%)) | 6 (14.3%) |
| Peripheral arterial disease (n (%)) | 3 (7.1%) |
| Stroke (n (%)) | 3 (7.1%) |
| Diabetes mellitus (n (%)) | 15 (35.7%) |
| Cardiovascular risk assessment | |
| ACC/AHA 10-year risk (%) | 21 ± 14 |
| Framingham 10-year general cardiovascular risk (%) | 22 ± 14 |
| Framingham 10-year coronary risk (%) | 15 ± 11 |
| Urate burden | |
| Serum urate (mg/dL) | 8.1 ± 2.3 |
| Subcutaneous (clinical) tophi (n (%)) | 12 (28.6%) |
| Ultrasound tophus (n (%)) | 29 (69%) |
| Ultrasound tophus volume (cm3) | 1.1 ± 1.4 |
| At least one joint with the double contour sign (n (%)) | 41 (97.6%) |
| DECT MSU volume knees (cm3) (n = 39) | 1.9 ± 4.6 |
| DECT MSU volume feet (cm3) (n = 41) | 2.7 ± 6.7 |
| DECT MSU volume knees + feet (cm3) (n = 38) | 4.7 ± 10.8 |
| Ongoing drugs | |
| Diuretics (n (%)) | 11 (26.2%) |
| Antidiabetic treatment (n (%)) | 15 (35.7%) |
| Hypolipidemic treatment (n (%)) | 16 (38.1%) |
| Treatment for high blood pressure (n (%)) | 25 (59.5%) |
ACC/AHA American College of Cardiology/American Heart Association, DECT dual-energy computed tomography, HDL high-density lipoprotein, LDL low-density lipoprotein, MSU monosodium urate